5:04 PM
 | 
Nov 12, 2013
 |  BC Extra  |  Clinical News

PsiOxus meets in Phase II cancer cachexia trial

PsiOxus Therapeutics Ltd. (Abingdon, U.K.) said twice-daily 10 mg oral MT-102 met the primary endpoint of greater weight gain over 16 weeks vs. placebo...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >